The State Drug Administration accepts a new drug application for the treatment of set cell lymphoma in Zanubrutinib, Baiji Shenzhou

lymphoma is a group of malignant tumors that originate in B cells, T cells, or NK cellsSet cell lymphoma (MCL) is usually an invasive non-Hodgkin's lymphoma (NHL) that originates from B cells in the "set area"today, Baiji Shenzhou announced that China's NationalPharmaceutical(the Supervisory Authority has accepted zanubrutinib, a Bruton's tyrosine kinase (BTK) inhibitor under study as anew drug(NDA) for potential therapies for patients with recurrent/incurable lymcinoloma (MCL)Zanubrutinib was discovered by Baiji Shenzhou's Research Center in Beijing, China, and is currently developing around the world for its use as a single drug and in combination with other therapies to treat a variety of blood malignancieszanubrutinib
Zanubruminib (BGB-3111), a small molecule inhibitor of Bruton's tyrosine kinase (BTK), is currently undergoing extensive pilotof key clinical(project, as a single drug and combined with other therapies) to treat multiple lymphomasas part of a wide range of global development projects, zanubrutinib is currently conducting research in a number of clinical trialsZanubrutinib was also recently granted fast-track status by the U.SFood and Drug Administration (
FDA) for the treatment of patients with Fahrenheit cytoproteinine (WM) Baiji Shenzhou plans to submit zanubrutinib to the FDA as a potential treatment for WM patients in the first half of 2019, based on the results of the Global Clinical Phase 1 trial in addition to the Global Clinical Phase 1 trial, zanubrutinib was evaluated in a global clinical Phase 3 trial of WM patients who had completed the patient enroll edifying compared to the currently approved BTK inhibitor ibitinib for treatment of WM 　　Zanubrutinib is also evaluated in a phase 3 clinical trial for untreated patients with chronic lymphocytic leukemia (CLL) and in a critical Phase 2 clinical trial in combination with GAZYVA ® (Obitojube) for the treatment of recurrent or refractory optoid lymphoma in China, Baiji Shenzhou has completed two other key Phase 2 clinical trials for patients treated with CLL and WM, respectively Baiji Shenzhou is planning a clinical phase 3 trial of Ibutinib in patients with recurrent/incurable CLL/small lymphocytic lymphoma (SLL) As of August 2018, more than 1,500 patients have been enrolled in the zanubrutinib clinical development program